Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.7158
-0.0893-11.09%
Post-market: 0.71990.0041+0.57%19:36 EDT
Volume:221.34K
Turnover:162.29K
Market Cap:2.41M
PE:-0.05
High:0.7618
Open:0.7498
Low:0.7093
Close:0.8051
52wk High:480.00
52wk Low:0.7093
Shares:3.37M
Float Shares:3.37M
Volume Ratio:3.10
T/O Rate:6.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.8013
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.19
PE(LYR):0.00

Loading ...

Clearmind Advances CMND-100 into Alcohol Use Disorder Patients After Phase I/II Safety Milestone

Reuters
·
Aug 13

Clearmind Advances Cmnd-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

THOMSON REUTERS
·
Aug 13

Clearmind Medicine Announces Positive Permeation Results for Intranasal Meai Formulation

Reuters
·
Aug 11

Clearmind Medicine reports MEAI development program permeation study results

TIPRANKS
·
Aug 11

Clearmind Medicine Reports Positive Permeation Results for Intranasal MEAI Formulation Study

Reuters
·
Aug 11

Clearmind Medicine - Intranasal Meai Shows Enhanced Nasal Retention Without Compromising Permeation

THOMSON REUTERS
·
Aug 11

Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study

TIPRANKS
·
Aug 06

Clearmind Advances CMND-100 Alcohol Use Disorder Trial into Patient Testing After Phase I Safety Readout

Reuters
·
Aug 06

Clearmind Reaches Key Clinical Trial Milestone as Dsmb Unanimously Clears Progression in AUD Study

THOMSON REUTERS
·
Aug 06

Clearmind Signs LOI to Buy 51% Stake in EV Wireless Charging Firm for $2.5 Million

Reuters
·
Aug 03

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - to Extend $1.50 Mln Loan at 4% Interest, Repayable in Two Years

THOMSON REUTERS
·
Aug 03

Clearmind Medicine - Deal Valued at $2.50 Mln for 51% Majority Stake

THOMSON REUTERS
·
Aug 03

Psychedelic: Clearmind reports safety findings for CMND-100

TIPRANKS
·
Jul 30

Clearmind Medicine announces safety results from Part A of CMND-100 tral

TIPRANKS
·
Jul 30

Clearmind Reports Positive Safety, Tolerability in Cmnd-100 Phase I/II Trial Part a Dose Escalation

Reuters
·
Jul 30

Clearmind Medicine - Study Achieves Primary Endpoint of Safety and Tolerability for Cmnd-100

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - no Serious Adverse Events Observed in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Announces Positive Safety Findings for Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part a of Its FDA-Regulated Clinical Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - All 24 Participants Successfully Complete Treatment in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30